Phosphatidylinositol 3-kinase (PI3K)

Overview

Phosphatidylinositol 3-kinase (PI3K) is a key regulatory enzyme involved in cellular signaling processes and a critical target in drug development for multiple disease indications. PI3K catalyzes the phosphorylation of phosphatidylinositol lipids in cell membranes, generating secondary messengers that activate downstream signaling cascades. The enzyme exists in multiple isoforms (notably PI3K-δ and PI3K-γ), each with distinct tissue distribution and functional roles in immune cells, vascular endothelial cells, and other cell types. As a central node in the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, PI3K regulates fundamental cellular processes including proliferation, survival, differentiation, and metabolism. Due to its dysregulation in various Cancers and inflammatory diseases, PI3K has emerged as a major pharmaceutical target, with multiple small-molecule inhibitors and combination therapeutic strategies currently under investigation.

Recent Publications Summary

Recent studies have continued to implicate phosphatidylinositol 3-kinase (PI3K) as a central signaling node in diverse disease models and therapeutic strategies. In experimental ischemic stroke, ergothioneine was reported to confer neuroprotection through activation of the PI3K/Akt/Nrf2 pathway, with reduced infarct volume, improved cerebral perfusion, and attenuation of glial cell activation in both photochemical ischemia and middle cerebral artery occlusion models 42214028May. In a diabetic rat model of cognitive decline, low-carbohydrate diet and Xiaokeping treatment were associated with analysis of PI3K/Akt signaling alongside improvements in body weight, glucose and lipid balance, oxidative stress markers, inflammatory factors, and hippocampal pathology 42324965Jun. In myocardial infarction induced by isoproterenol, dimethyl fumarate was linked to modulation of the NRG-1/ErbB2/Akt axis, with cardiac tissue levels of PI3K and Akt-1 measured as part of the mechanistic assessment and with reduced serum injury markers and improved oxidative balance 42229738Jun.

PI3K has also been studied in cancer-focused combination approaches. A phase II trial in relapsed/refractory peripheral T-cell lymphoma evaluated duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, and reported deep clinical responses with an objective response rate of 48.0% and a complete response rate of 33.3% in the expansion cohort 42018969Apr. In acute myeloid leukemia cells, selective inhibition of PI3K and/or BCL-2 enhanced the cytotoxic and pro-apoptotic effects of gemtuzumab ozogamicin in both sensitive and resistant cell lines, with the strongest effects observed in triple-combination settings 41980559Apr. Another study examined the addition of BKM120, a PI3K inhibitor, to BI-3406 plus trametinib, focusing on the balance between efficacy and side effects in a combinatorial cancer therapy context 42399819Jul.

Beyond these settings, PI3K was also incorporated into metabolic and tissue-repair studies. In metabolic dysfunction-associated steatotic liver disease, Jinshanxiaoke granules were reported to alleviate hepatic lipid dysregulation through Ampk/Ppar-α and Pi3k/Akt-mediated restoration of lipid homeostasis 41990925Apr. In skin wound healing, ADSC-derived exosomes engineered with bFGF were designed to promote repair, with the study specifically aiming to clarify whether therapeutic effects correlated with PI3K/Akt signaling pathway activation 42461467Jul. In an Alzheimer’s disease mouse model, chronic lithium exposure reshaped PI3K-mTOR-linked proteostatic networks in the hippocampus, and network analysis identified proteins associated with PI3K signaling among shared APP-, MAPT-, and PI3K-related datasets 42410183Jul.

What Changes, What Holds

1. PI3K remains a broadly relevant signaling node across ischemic, metabolic, and cardiac injury models
REINFORCES These studies extend the baseline’s view of PI3K as a central regulator of proliferation, survival, and metabolism by repeatedly placing PI3K/Akt-linked signaling in injury-response settings. They do not displace the established account; instead, they support the idea that PI3K is a common mechanistic hub in diverse nonmalignant disease models, including neuroprotection, metabolic dysfunction, and myocardial injury 42214028May42324965Jun.

2. PI3K inhibition continues to look clinically useful in hematologic malignancy combinations, but the best role remains regimen-dependent
REINFORCES The duvelisib trial strengthens the baseline claim that PI3K is a major pharmaceutical target in cancer, especially through PI3K-δ/γ inhibition in immune-cell malignancies. The combination studies in leukemia and with BKM120 do not overturn that account; they instead suggest that PI3K-directed therapy may be most effective as part of multi-agent strategies, while also underscoring that efficacy and toxicity tradeoffs still need definition 42018969Apr41980559Apr.

3. PI3K is being used beyond cancer and inflammation as a mechanistic handle in liver repair, wound healing, and neurodegeneration
NEW DIRECTION These reports do not contradict the baseline, but they broaden it into roles the overview does not yet cover: PI3K/Akt-linked signaling is being invoked in steatotic liver disease, engineered exosome-mediated wound repair, and lithium-associated proteostatic remodeling in Alzheimer’s disease models. The common thread is not a new core function, but a wider translational footprint that still needs causal validation in each setting 41990925Apr42461467Jul42410183Jul.

Overview update candidates: PI3K involvement in nonmalignant injury and repair models; PI3K-directed combination therapy as a recurring strategy in cancer; broader disease applications in metabolic liver disease; wound healing; and neurodegeneration.